(PRE) Prenetics Global - Ratings and Ratios

Prenetics Global Limited (NASDAQ:PRE) is a health sciences company specializing in consumer and clinical health solutions. Its consumer health initiatives are spearheaded by IM8, a newly launched brand focused on holistic wellness. The companys prevention segment, CircleDNA, leverages next-generation sequencing (NGS) to provide comprehensive DNA testing for consumers. Additionally, Prenetics develops and commercializes advanced multi-cancer early detection technologies, offering precision oncology solutions. Its genomic profiling portfolio includes ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, designed to meet specific clinical requirements. The company also offers ACTLiquid Pro, a sequencing-based liquid biopsy assay for solid tumors, and ACTMonitor, which enables real-time tracking of drug resistance, treatment response, and cancer recurrence. Furthermore, Prenetics provides ACTRisk for cancer risk management. Beyond diagnostics, the company operates in sports distribution, supplying nutrition products to fitness facilities. With operations in Taiwan, Hong Kong, the UK, and the U.S., Prenetics was founded in 2014 and is headquartered in Quarry Bay, Hong Kong. Web URL: https://www.prenetics.com

From a technical standpoint, Prenetics Global Ltd (NASDAQ:PRE) is trading at $4.79 with a 20-day average volume of 7,871 shares. Its short-term moving averages (SMA 20 and SMA 50) are at $5.19 and $5.46, respectively, while the SMA 200 stands at $5.25. The Average True Range (ATR) is 0.31, indicating moderate price volatility. On the fundamental side, the company has a market cap of $62.80M, with a price-to-book (P/B) ratio of 0.35 and a price-to-sales (P/S) ratio of 2.46. The return on equity (RoE) is reported at -27.43%, reflecting current profitability challenges.

3-Month Forecast: - Technical Outlook: The stock is likely to face resistance at the SMA 50 ($5.46) and SMA 200 ($5.25). Support levels may emerge near the current price ($4.79) and the lower end of the ATR range ($4.48). Expect sideways movement with occasional bearish pressure due to the downward trend in moving averages. - Fundamental Outlook: With a P/S ratio of 2.46, the market may view the stock as undervalued if revenue growth accelerates. However, the negative RoE (-27.43%) suggests operational inefficiencies that could weigh on investor sentiment. The companys ability to scale its genomic profiling and liquid biopsy solutions will be critical in the near term.